Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 4863079, 14 pages
https://doi.org/10.1155/2017/4863079
Review Article

Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research

1Department of Anesthesiology, Loma Linda University Medical Center, Loma Linda, CA 92354, USA
2Department of Physiology and Pharmacology, Loma Linda University School of Medicine, 11041 Campus Street, Risley Hall, Room 219, Loma Linda, CA 92354, USA
3Department of Neurosurgery, University Hospital Innsbruck, 6020 Tyrol, Austria
4Department of Neurosurgery, Loma Linda University School of Medicine, Loma Linda, CA 92354, USA

Correspondence should be addressed to John H. Zhang; moc.oohay@0193gnahznhoj

Received 27 September 2016; Accepted 23 November 2016; Published 14 February 2017

Academic Editor: Nicola Simola

Copyright © 2017 Cesar Reis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. A. Seifert and K. R. Pennypacker, “Molecular and cellular immune responses to ischemic brain injury,” Translational Stroke Research, vol. 5, no. 5, pp. 543–553, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Lippi, M. Montagnana, E. Danese, E. J. Favaloro, and M. Franchini, “Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy,” Biomarkers in Medicine, vol. 5, no. 1, pp. 63–70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. A. M. Pancioli, J. Broderick, T. Brott et al., “The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the clear stroke trial,” Stroke, vol. 39, no. 12, pp. 3268–3276, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Khatri, L. R. Wechsler, and J. P. Broderick, “Intracranial hemorrhage associated with revascularization therapies,” Stroke, vol. 38, no. 2, pp. 431–440, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. A. M. Pancioli, O. Adeoye, P. A. Schmit et al., “Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial,” Stroke, vol. 44, no. 9, pp. 2381–2387, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Adeoye, H. Sucharew, J. Khoury et al., “Combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator in acute ischemic stroke-full dose regimen stroke trial,” Stroke, vol. 46, no. 9, pp. 2529–2533, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Ungerer, K. Rosport, A. Bültmann et al., “Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans,” Circulation, vol. 123, no. 17, pp. 1891–1899, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Goyal, A. M. Demchuk, B. K. Menon et al., “Randomized assessment of rapid endovascular treatment of ischemic stroke,” New England Journal of Medicine, vol. 372, no. 11, pp. 1019–1030, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. A. I. Qureshi, P. Harris-Lane, J. F. Kirmani et al., “Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study,” Neurosurgery, vol. 59, no. 4, pp. 789–796, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Parsons, N. Spratt, A. Bivard et al., “A randomized trial of tenecteplase versus alteplase for acute ischemic stroke,” The New England Journal of Medicine, vol. 366, no. 12, pp. 1099–1107, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Huang, B. K. Cheripelli, S. M. Lloyd et al., “Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study,” The Lancet Neurology, vol. 14, no. 4, pp. 368–376, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. S. C. Cramer, B. Abila, N. E. Scott, M. Simeoni, and L. A. Enney, “Safety, pharmacokinetics, and pharmacodynamics of escalating repeat doses of GSK249320 in patients with stroke,” Stroke, vol. 44, no. 5, pp. 1337–1342, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Abila, E. Cunningham, and M. Simeoni, “First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers,” Clinical Pharmacology and Therapeutics, vol. 93, no. 2, pp. 163–169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M. S. V. Elkind, R. L. Sacco, R. B. Macarthur et al., “The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke,” International Journal of Stroke, vol. 3, no. 3, pp. 210–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. F. Meschia, R. B. McNeil, K. M. Barrett, T. G. Brott, N. R. Graff-Radford, and R. D. Brown Jr., “Mayo Acute Stroke Trial for Enhancing Recovery (MASTER) protocol,” Journal of Stroke and Cerebrovascular Diseases, vol. 19, no. 4, pp. 299–310, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Urfer, H. J. Moebius, D. Skoloudik et al., “Phase II trial of the sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke,” Stroke, vol. 45, no. 11, pp. 3304–3310, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Martin-Schild, H. Hallevi, H. Shaltoni et al., “Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke: a pilot study of caffeinol and mild hypothermia,” Journal of Stroke and Cerebrovascular Diseases, vol. 18, no. 2, pp. 86–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Kaste, S. Murayama, G. A. Ford, D. W. J. Dippel, M. R. Walters, and T. Tatlisumak, “Safety, tolerability and pharmacokinetics of mci-186 in patients with acute ischemic stroke: new formulation and dosing regimen,” Cerebrovascular Diseases, vol. 36, no. 3, pp. 196–204, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. K. N. Sheth, W. T. Kimberly, J. J. Elm et al., “Pilot study of intravenous glyburide in patients with a large ischemic stroke,” Stroke, vol. 45, no. 1, pp. 281–283, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. K. N. Sheth, J. J. Elm, L. A. Beslow, G. K. Sze, and W. T. Kimberly, “Glyburide advantage in malignant edema and stroke (GAMES-RP) trial: rationale and design,” Neurocritical Care, vol. 24, no. 1, pp. 132–139, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. W.-C. Shyu, S.-Z. Lin, C.-C. Lee, D. D. Liu, and H. Li, “Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial,” Canadian Medical Association Journal, vol. 174, no. 7, pp. 927–933, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Moriya, A. Mizuma, T. Uesugi et al., “Phase I study of intravenous low-dose granulocyte colony-stimulating factor in acute and subacute ischemic stroke,” Journal of Stroke and Cerebrovascular Diseases, vol. 22, no. 7, pp. 1088–1097, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. W. R. Schäbitz, R. Laage, G. Vogt et al., “AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke,” Stroke, vol. 41, no. 11, pp. 2545–2551, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. E. B. Ringelstein, V. Thijs, B. Norrving et al., “Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for ischemic stroke trial,” Stroke, vol. 44, no. 10, pp. 2681–2687, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. A. M. Alasheev, A. A. Belkin, I. N. Leiderman, R. A. Ivanov, and T. M. Isakova, “Granulocyte-colony-stimulating factor for acute ischemic stroke: a randomized controlled trial (STEMTHER),” Translational Stroke Research, vol. 2, no. 3, pp. 358–365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Lyden, H. Levy, S. Weymer et al., “Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers,” Current Pharmaceutical Design, vol. 19, no. 42, pp. 7479–7485, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. A. I. Qureshi, M. F. K. Suri, Z. Ali et al., “Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke. A preliminary feasibility and safety study in a non-human primate model,” Neuroradiology, vol. 47, no. 11, pp. 845–854, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. P. A. Lapchak, J. H. Zhang, and L. J. Noble-Haeusslein, “RIGOR guidelines: escalating STAIR and STEPS for effective translational research,” Translational Stroke Research, vol. 4, no. 3, pp. 279–285, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. B. C. V. Campbell, P. J. Mitchell, T. J. Kleinig et al., “Endovascular therapy for ischemic stroke with perfusion-imaging selection,” New England Journal of Medicine, vol. 372, no. 11, pp. 1009–1018, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. J. L. Saver, M. Goyal, A. Bonafe et al., “Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke,” International Journal of Stroke, vol. 10, no. 3, pp. 439–448, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Squizzato, E. Romualdi, F. Dentali, and W. Ageno, “Statins for acute ischemic stroke,” Cochrane Database of Systematic Reviews, no. 8, Article ID CD007551, 2011. View at Google Scholar · View at Scopus
  32. C.-J. Chen, D. Ding, R. M. Starke et al., “Endovascular vs medical management of acute ischemic stroke,” Neurology, vol. 85, no. 22, pp. 1980–1990, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Carloni, S. Girelli, G. Buonocore, M. Longini, and W. Balduini, “Simvastatin acutely reduces ischemic brain damage in the immature rat via Akt and CREB activation,” Experimental Neurology, vol. 220, no. 1, pp. 82–89, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Shehadah, J. Chen, X. Cui, C. Roberts, M. Lu, and M. Chopp, “Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome,” Journal of the Neurological Sciences, vol. 294, no. 1-2, pp. 107–111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. S. V. Elkind, R. L. Sacco, R. B. MacArthur et al., “High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART),” Cerebrovascular Diseases, vol. 28, no. 3, pp. 266–275, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. C. M. Atkins, “Decoding hippocampal signaling deficits after traumatic brain injury,” Translational Stroke Research, vol. 2, no. 4, pp. 546–555, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. M. L. Berthier, J. Hinojosa, M. D. C. Martín, and I. Fernández, “Open-label study of donepezil in chronic poststroke aphasia,” Neurology, vol. 60, no. 7, pp. 1218–1219, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. P. M. Doraiswamy, M. A. Babyak, T. Hennig et al., “Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial,” Psychopharmacology Bulletin, vol. 40, no. 2, pp. 54–62, 2007. View at Google Scholar · View at Scopus
  39. M. L. Berthier, C. Green, C. Higueras, I. Fernández, J. Hinojosa, and M. C. Martín, “A randomized, placebo-controlled study of donepezil in poststroke aphasia,” Neurology, vol. 67, no. 9, pp. 1687–1689, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. S. E. Nadeau, A. L. Behrman, S. E. Davis et al., “Donepezil as an adjuvant to constraint-induced therapy for upper-limb dysfunction after stroke: an exploratory randomized clinical trial,” Journal of Rehabilitation Research and Development, vol. 41, no. 4, pp. 525–534, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Paolucci, I. Bureca, M. Multari, U. Nocentini, and A. Matano, “An open-label pilot study of the use of rivastigmine to promote functional recovery in patients with unilateral spatial neglect due to first ischemic stroke,” Functional Neurology, vol. 25, no. 4, pp. 195–200, 2010. View at Google Scholar · View at Scopus
  42. E. M. Whyte, E. J. Lenze, M. Butters et al., “An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients,” Cerebrovascular Diseases, vol. 26, no. 3, pp. 317–321, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Fujiki, H. Kobayashi, S. Uchida, R. Inoue, and K. Ishii, “Neuroprotective effect of donepezil, a nicotinic acetylcholine-receptor activator, on cerebral infarction in rats,” Brain Research, vol. 1043, no. 1-2, pp. 236–241, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. K. M. Barrett, T. G. Brott, R. D. Brown Jr. et al., “Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a phase iia clinical trial,” Journal of Stroke and Cerebrovascular Diseases, vol. 20, no. 3, pp. 177–182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. I. Solaroglu, M. Digicaylioglu, G. E. Keles, and J. H. Zhang, “New missions for an old agent: granulocyte-colony stimulating factor in the treatment of stroke patients,” Current Medicinal Chemistry, vol. 22, no. 10, pp. 1302–1309, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Boy, S. Sauerbruch, M. Kraemer et al., “Mobilisation of hematopoietic CD34+ precursor cells in patients with acute stroke is safe—results of an open-labeled non randomized phase I/II trial,” PLoS ONE, vol. 6, no. 8, Article ID e23099, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Yamashita, G.-W. Sun, Y. Cui et al., “Neuroprotective effects of cutamesine, a ligand of the sigma-1 receptor chaperone, against noise-induced hearing loss,” Journal of Neuroscience Research, vol. 93, no. 5, pp. 788–795, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Niitsu, M. Iyo, and K. Hashimoto, “Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases,” Current Pharmaceutical Design, vol. 18, no. 7, pp. 875–883, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Ono, H. Tanaka, M. Takata et al., “SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models,” Neuroscience Letters, vol. 559, pp. 174–178, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Ruscher, A. R. Inácio, K. Valind, A. R. Ravan, E. Kuric, and T. Wieloch, “Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke,” PLoS ONE, vol. 7, no. 9, Article ID e45118, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. B. B. Fredholm, K. Bättig, J. Holmén, A. Nehlig, and E. E. Zvartau, “Actions of caffeine in the brain with special reference to factors that contribute to its widespread use,” Pharmacological Reviews, vol. 51, no. 1, pp. 83–133, 1999. View at Google Scholar · View at Scopus
  52. L. Belayev, L. Khoutorova, Y. Zhang et al., “Caffeinol confers cortical but not subcortical neuroprotection after transient focal cerebral ischemia in rats,” Brain Research, vol. 1008, no. 2, pp. 278–283, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. X. Zhao, R. Strong, P. Piriyawat, R. Palusinski, J. C. Grotta, and J. Aronowski, “Caffeinol at the receptor level: anti-ischemic effect of n-methyl-d-aspartate receptor blockade is potentiated by caffeine,” Stroke, vol. 41, no. 2, pp. 363–367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. P. A. Lapchak, D. Song, J. Wei, and J. A. Zivin, “Pharmacology of caffeinol in embolized rabbits: clinical rating scores and intracerebral hemorrhage incidence,” Experimental Neurology, vol. 188, no. 2, pp. 286–291, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Wada, H. Yasunaga, R. Inokuchi et al., “Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator,” Journal of the Neurological Sciences, vol. 345, no. 1, pp. 106–111, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Khanna, K. T. Kahle, B. P. Walcott, V. Gerzanich, and J. M. Simard, “Disruption of ion homeostasis in the neurogliovascular unit underlies the pathogenesis of ischemic cerebral edema,” Translational Stroke Research, vol. 5, no. 1, pp. 3–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. F. J. Ortega, J. Gimeno-Bayon, J. F. Espinosa-Parrilla et al., “ATP-dependent potassium channel blockade strengthens microglial neuroprotection after hypoxia-ischemia in rats,” Experimental Neurology, vol. 235, no. 1, pp. 282–296, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. D. M. Abdallah, N. N. Nassar, and R. M. Abd-El-Salam, “Glibenclamide ameliorates ischemia-reperfusion injury via modulating oxidative stress and inflammatory mediators in the rat hippocampus,” Brain Research, vol. 1385, pp. 257–262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. W. T. Kimberly, T. W. K. Battey, L. Pham et al., “Glyburide is associated with attenuated vasogenic edema in stroke patients,” Neurocritical Care, vol. 20, no. 2, pp. 193–201, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. E. M. Gleeson, M. G. Dichiara, A. Salicio et al., “Activated protein C β-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury,” Blood, vol. 126, no. 7, pp. 915–919, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Wang, Z. Zhao, N. Chow et al., “Activated protein c analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats,” Stroke, vol. 44, no. 12, pp. 3529–3536, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. T. Cheng, A. L. Petraglia, Z. Li et al., “Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage,” Nature Medicine, vol. 12, no. 11, pp. 1278–1285, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Wang, Z. Zhang, N. Chow et al., “An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents,” Stroke, vol. 43, no. 9, pp. 2444–2449, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. B. V. Zlokovic, C. Zhang, D. Liu, J. Fernandez, J. H. Griffin, and M. Chopp, “Functional recovery after embolic stroke in rodents by activated protein C,” Annals of Neurology, vol. 58, no. 3, pp. 474–477, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. L. O. Mosnier, J. A. Fernández, T. P. Davis, B. V. Zlokovic, and J. H. Griffin, “Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity,” Journal of Thrombosis and Haemostasis, vol. 11, no. 11, pp. 2059–2062, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Cheng, D. Liu, J. H. Griffin et al., “Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective,” Nature Medicine, vol. 9, no. 3, pp. 338–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. H. Guo, I. Singh, Y. Wang et al., “Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity,” European Journal of Neuroscience, vol. 29, no. 6, pp. 1119–1130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Kikuchi, E. Tanaka, Y. Murai, and S. Tancharoen, “Clinical trials in acute ischemic stroke,” CNS Drugs, vol. 28, no. 10, pp. 929–938, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. K. W. Muir, “Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design,” Stroke, vol. 33, no. 6, pp. 1545–1550, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. A. J. Furlan, “Challenges in acute ischemic stroke clinical trials,” Current Cardiology Reports, vol. 14, no. 6, pp. 761–766, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Fisher, “New approaches to neuroprotective drug development,” Stroke, vol. 42, no. 1, supplement, pp. S24–S27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. U. Dirnagl, “Pathobiology of injury after stroke: the neurovascular unit and beyond,” Annals of the New York Academy of Sciences, vol. 1268, no. 1, pp. 21–25, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. Stroke Therapy Academic Industry Roundtable II (STAIR-II), “Recommendations for clinical trial evaluation of acute stroke therapies,” Stroke, vol. 32, no. 7, pp. 1598–1606, 2001. View at Publisher · View at Google Scholar
  74. C. Ellimoottil, S. Vijan, and R. C. Flanigan, “A primer on clinical trial design,” Urologic Oncology, vol. 33, no. 3, pp. 116–121, 2015. View at Publisher · View at Google Scholar · View at Scopus